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Abstract
Cardiovascular disease is the leading cause of morbidity and mortality among peo‐
ple with diabetes worldwide, accounting for 60% of all deaths in diabetics. Despite
advances in our pathophysiologic understanding of diabetic co-morbidities and
measures to help counter these, diabetics still remain at increased risk for cardiovas‐
cular disease complicating our overall approach to management. Diabetics, in par‐
ticularly type 2, are often fraught with additional risk factors contributing to their
overall propensity for developing cardiovascular disease. These include, but are not
limited to, obesity, dyslipidemia, poor glycemic control, lack of physical activity,
and hypertension. In response to this, research driven guidelines focusing on pri‐
mary prevention have continued to arise with new clinical targets and goals sub‐
stantially changing our approach with the diabetic population. It is important to
note early on, type 1 diabetics carry a higher risk of cardiovascular disease for
which the pathophysiology is only recently being elucidated. The underlying rela‐
tionship between cardiovascular events and risk factors is, however, not well un‐
derstood. For this reason, management approaches to risk reduction have been
extrapolated from experience in type 2 diabetes mellitus. The purpose of this chap‐
ter is to present the conclusions of current literature pertaining to blood pressure
and blood glucose control, cholesterol management, aspirin therapy, and lifestyle
modification. We present a synthesis of the new guidelines, and clinical targets, in‐
cluding preventative measures for subclinical cardiovascular disease for the con‐
temporary management of patients with diabetes mellitus.
Keywords: Diabetes, atherosclerosis, coronary artery disease, glycemic control, antidia‐
betic medications
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1. Introduction
1.1. Diabetes and cardiovascular risk: Scope of the problem
Cardiovascular disease (CVD) is the major cause of morbidity and mortality in the diabetic
population which is rapidly expanding around the globe and is increasing due to the rising
epidemic of obesity and increasing sedentary lifestyle along with poor dietary habits.[1] The
cardiovascular events associated with type 2 diabetes and the high incidence of other macro‐
vascular complications, such as strokes and amputations, are major causes of illnesses and a
large economic burden. Heart disease and strokes account for over 2/3 of mortality in the
diabetic population who are 2–4 times more likely to have atherosclerotic heart disease
compared to non-diabetic individuals. In fact, diabetes itself is considered a cardiovascular
risk equivalent and the diabetic population is less likely to survive when they develop CVD,
compared to their non-diabetic counterparts. While the additional risk diabetes confers cannot
be completely eliminated, large benefit is seen when multiple risk factors and associated
comorbid conditions are addressed globally in this patient population and addressed specif‐
ically with respect to treatment targets and goals.
1.2. Risk factors for cardiovascular disease in diabetes
Risk factors for increased CVD among people with diabetes include traditional ones such as
insulin resistance, hypertension, dyslipidemia, central obesity, and cigarette smoking. Non-
traditional risk factors include microalbuminuria, increased inflammation, oxidative stress,
hyperuricemia, hypercoagulable states, endothelial dysfunction, decrease nitric oxide func‐
tion, increase vascular reactivity and permeability, increased glycated end products, as well
as stimulation of the renin angiotensin aldosterone (RAAS) system.
Modifiable Risk Factors Non-modifiable Risk Factors
Overweight/obesity Family history of diabetes or premature coronary disease
Sedentary lifestyle Latino/Hispanic, Non-Hispanic black, Asian American,
Native American, or Pacific Islander ethnicity
Hypertension History of gestational diabetes
Elevated LDL-C and/or triglycerides and/or low HDL-C History of infant delivery birth weight "/>9 pounds
Psychiatric illness Polycystic ovarian syndrome
IGT, IFG Age
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; IFG, impaired fasting
glucose; IGT, impaired glucose tolerance
Adapted from Diabetes Care Volume 38, Supplement 1, January 2015 [2]
Table 1. Modifiable and non-modifiable risk factors associated with type 2 diabetes mellitus and cardiovascular
disease
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1.3. Hypertension
Hypertension is the most common comorbid disease associated with diabetes. It has been
found to increase the risk of nephropathy, retinopathy, left ventricular hypertrophy, and
cardiovascular events.[3] Prevention of these vascular complications is a worldwide priority
as the prevalence of diabetics by 2030 is estimated to be approximately 350 million.[4] As a
result, blood pressure (BP) management is arguably one of the more critical aspects of the care
of the patient with diabetes. The current 2015 American Diabetes Association (ADA) recom‐
mendations are for all diabetics to achieve a systolic blood pressure (SBP) of <140 and a diastolic
blood pressure (DBP) of <90. This has been revised to reflect the most recent high-quality
evidence that exists to support a goal of DBP, 90 mmHg. Although, it has been traditionally
recommended that diabetics achieve a blood pressure of less of 130/80, there is insufficient
evidence to justify the benefit of this value.[5] While hypertension therapy is not the main focus
of this chapter, it is important to realize that lifestyle therapy for hypertension should be offered
to all patients as a reasonable first intervention; this includes weight loss, increased physical
activity, and a Dietary Approaches to Stop Hypertension (DASH)–style diet. If despite this the
patient is unable to achieve the goal BP pharmacological therapy should comprise a regimen
that includes either an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor
inhibitor (ARB)–either of which are effective in preventing the development or progression of
microalbuminuria which reduces the incidence of new or worsening nephropathy.[6]
2. Hyperglycemia and cardiovascular risk
Hyperglycemia, even in the non-diabetic range such as impaired fasting glucose and/or
impaired glucose tolerance (collectively classified as pre-diabetes) is associated with increased
risk of coronary artery disease. This has been shown in several trials and also evidence exists
that glycemic control is associated with decreased coronary artery disease. For example, the
landmark United Kingdom Diabetes Perspective Study (UKPDS) showed a graded risk
reduction in myocardial infarction among the diabetic population with 14% decreased risk for
every 1% decrease in A1C. Glucose control is important and associated with decreased
microvascular complications such as diabetic nephropathy, retinopathy, as well as neuropa‐
thy, with about 30% risk reduction with each 1% decrease in A1C, as evidenced from large
trials in type 1 DM such as Diabetes Complication (DCCT) in type 1 diabetes and from UKPDS
study in type 2 diabetes in patient with new onset/early onset diabetes.[7]
Long term follow up of these cohorts also provided evidence of decreased macrovascular
disease such as in the Epidemiology of Diabetes Interventions and Complications (EDIC), a
follow up of the DCCT trial where intensive blood glucose control reduced risk of any CVD
event by 42% and the risk of nonfatal myocardial infarction, stroke, or death from cardiovas‐
cular causes by 57%.[8] However, tight glycemic control has been shown to be associated with
increased mortality among high-risk population. In the large randomized controlled trial,
ACCORD (Action to Control Cardiovascular Risk in Diabetes), tight control of blood glucose
to a hemoglobin A1C of 6.4%, compared to 7.5% in the control group, was associated with a
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22% increased mortality leading to premature termination of the study protocol. Furthermore,
there was increased risk of hypoglycemia requiring assistance and an average of 10 kg weight
gain in the period of 3.5 years of follow up. This study, as well as others, triggered a Position
Statement by the American Diabetes Association (ADA) and the European Association for the
Study of Diabetes (EASD) calling for an individualized patient approach with less stringent
glycemic control for patients with established vascular complications, as well as those with
longer diabetes duration and increased risk of hypoglycemia such as those with CKD and the
elderly with long standing diabetes and neuropathy.
2.1. Cardiovascular disease in the high-risk diabetic sub-population
Diabetes disproportionately affects minority populations such as blacks, Hispanics, Native
Americans, and South Asians. In these populations, the prevalence of diabetes is much higher
compared to Whites and they are disproportionately affected by diabetes complications
including chronic kidney disease, strokes, and coronary artery disease.
Premenopausal women with diabetes lose the estrogen protective effects that are partially
mediated through nitric oxide and women with diabetes have worse outcomes compared to
men when presented with acute coronary syndrome. Despite advances in the diagnosis and
treatment of acute coronary syndrome, and through improved medical therapies such as
revascularization, improved survival among men and women without diabetes as well as men
with diabetes has been observed, but evidence suggests worse prognosis for women with
diabetes remains.
2.2. Screening for cardiovascular disease
Screening of asymptomatic patients with high CVD risk is not recommended, as there have
been no trials that demonstrate improved outcomes even in the setting of angiographically
defined coronary disease. One of the largest trials to address this concern was the Detection
of Ischemia in Asymptomatic Diabetics (DIAD) study. DIAD randomized 1,123 subjects into
two categories: those who would and would not be screened with stress myocardial perfusion
imaging (MPI). Despite abnormal myocardial perfusion imaging in more than one in five
patients, cardiac events were lower than expected and equivalent in screened versus
unscreened patients.[9] Furthermore, trials including the COURAGE and BARI 2D have
shown no difference between revascularization and optimal medical therapy in patients who
are effected by stable coronary disease supporting a less invasive approach to management.
[10,11] The favorable cardiac outcomes among asymptomatic diabetics can likely be attributed
to guideline-driven management of cardiac risk factors. Therefore, the current standard of care
for type 2 diabetes should focus on the reduction of cardiovascular risk factors with avoidance
of indiscriminate screening.
2.3. Type I diabetes mellitus
Type I diabetes is a challenging clinical entity. It deserves separate mention as its management
has lagged in success when compared to type II diabetes.
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Type I diabetes is associated with an increased risk of early death with acute diabetes-related
complications responsible for the majority of younger deaths and cardiovascular disease the
main cause for older patients.[12,13,14] CVD occurs much earlier in type I diabetics than in the
general population—often after 2 decades of disease. This can occur as early as 30 years of age
disease rates of >3% per year.[15] Poor glycemic control has correlated to cardiovascular risk
(Table 2), however, the success rates of achieving optimal A1c levels is far from ideal. In two
national registries, only 13% to 15% of patients with type 1 diabetes met a target A1c level of
<7%.[16,13] The difficulty partially lies in dietary/insulin regimen adherence and risks of tight
blood sugar control (absolute risk of severe hypoglycemia increasing with tighter control).[6]
Mean HbA1c Death from any cause Death from cardiovascular disease
≤ 6.9% 2.36 (95%CI: 1.97–2.83) 2.92 (95%CI: 2.07–4.13)
7.0%–7.8% 2.38 (95%CI: 2.02–2.80) 3.39 (95%CI: 2.49–4.61)
7.9%–8.7% 3.11 (95%CI: 2.66–3.62) 4.44 (95%CI: 3.32–5.96)
8.8%–9.6% 3.65 (95%CI: 3.11–4.30) 5.35 (95%CI: 3.94–7.26)
≥ 9.7% 8.51 (95%CI: 7.24–10.01) 10.46 (95%CI: 7.62–14.37)
Adapted from Lind et al [11].
Table 2. Adjusted hazard ratios for death from any cause and death from cardiovascular disease among individuals
with type 1 diabetes vs control according to the glycated hemoglobin
Even when target glycemic control is achieved, the risk of death from cardiovascular causes
is more than twice the risk in the general population and poor glycemic control portends a risk
ten times higher.[17] The issue is complicated by several components highlighted by the
Scottish Registry Linkage Study. Unlike type 2 diabetics, type 1 diabetics generally do not
suffer from obesity and hypertension/dyslipidemia rates are not in excess of the general
population.[18] At this time, there is no clear explanation for the additional risk. It is postulated
that earlier onset and severely altered glucose homeostasis produces a variety of oxidative
stressors promoting a milieu of underlying vascular disease. This may be especially true in the
preadolescent years where subclinical disease manifests, priming the cardiovascular system
for accelerated atherosclerosis despite the best efforts at achieving glycemic control later in
life.[19] The term coined, metabolic memory, has been used to denote this theoretical process.
The phenomenon gained support after a significant trend was noted at the conclusion of the
DCCT and follow-up EDIC trial in regards to microvascular complications, e.g. nephropathy,
retinopathy. In summary, the DCCT trial ended with a transition of participants to an intensive
insulin regimen secondary to successful glycemic control and reduction in microvascular
complications with this method. Interestingly, as the same patients were followed, those
originally on the standard insulin regimen continued to have higher incidences of microvas‐
cular disease when compared to their counterpart. This occurred despite achieving near
equivalent A1c levels.[20,21,22] The notion of early vascular stress portending a worse
prognosis was also echoed in a recent Cochrane review where findings concluded that tight
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control reduced the risk of developing microvascular diabetes complications (the risk for
macrovascular complications was less clear secondary to the younger patient population they
examined), but the impact became weaker once complications manifested.[23] Furthermore,
during the EDIC study, macrovascular relationship became more apparent. Those participants
who initially were under the intensive regimen experienced a 42% reduction in CVD events
after 17 years. The ongoing EDIC showed these benefits persisted up to 10 years after the end
of the DCCT.[7,24,25,26] These findings are promising as more effort is being placed at
identifying subjects and initiating treatment earlier. Early therapy stands to eliminate or reduce
a large amount of complications; however, longer-term studies are still needed to realize the
full potential. It is also still unclear why cardiovascular complications start so early in the
disease history when, presumably, only mild hyperglycemia exists.
3. Multifactorial therapy: A comprehensive evidence based approach
Over the past two decades, diabetes management has evolved substantially as epidemiologic
and therapeutic based research has broadened our understanding of this complex disease. As
a general principle, diabetes magnifies many of the indolent cardiovascular risk factors for
morbidity and mortality amongst non-diabetic patients. As the population of diabetics
increases, there is a growing effort to acknowledge the risks and lessen them to the best of our
abilities. This begins with addressing modifiable risk factors for late complications in patients
which includes hyperglycemia, hypertension, and dyslipidemia—all of which increase the risk
of a poor outcomes.
Intensive treatment of multiple cardiovascular risk factors can have a major impact among
patients with diabetes. Reduction in glycosylated hemoglobin values, systolic and diastolic
blood pressure, fasting serum cholesterol and triglyceride levels, and urinary albumin
excretion rate all have their value in reducing cardiovascular morbidity and mortality. Up until
the turn of the century, numerous randomized trials investigated the effect of intensified
intervention involving a single risk factor in patients with type 2 diabetes demonstrating
benefits in terms of both macrovascular and microvascular complications in kidneys, eyes, and
nerves.[27,28,29,30,31] This formed the basis of American Diabetes Association recommenda‐
tions for many years which were finally bolstered by the landmark publication, Steno-2 study,
which investigated a multifactorial, goal directed strategy involving lifestyle modification and
pharmacologic management addressing all major metrics. An unrivalled 50% reduction in the
risk of macro and micro-vascular events was demonstrated in those who received intensive
treatment.[32] Since this study, several further trials have replicated these findings and have
shown that the benefit of aggressive lifestyle and multi-drug therapy is effective and should
be coupled with timely screening to confer a life-long benefit.[33,34,35]
3.1. Dietary management
Diet is one of the most important behavioral aspects of diabetes treatment, slowing and
potentially preventing the rate of developing complications. Basic principles of nutritional
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management have evolved over the past decade from a generalized approach to an individ‐
ualized one in the form of medical nutrition therapy (MNT). This approach takes scientific
evidence, individual goals and abilities into consideration to formulate lifestyle changes that
can be maintained. It is monitored and guided by a dietician or nutritionist with regular follow
up. Goals of MNT that apply to individuals with diabetes include achieving and maintaining
(1) blood glucose levels in the normal range or as close to normal as is safely possible, (2) a
lipid and lipoprotein profile that reduces the risk for vascular disease, (3) blood pressure levels
in the normal range or as close to normal as is safely possible, (4) to prevent, or at least slow,
the rate of development of the chronic complications of diabetes by modifying nutrient intake
and lifestyle to address individual nutrition needs, taking into account personal and cultural
preferences and willingness to change, and (5) the pleasure of eating by only limiting food
choices when indicated by scientific evidence.[36] By the mid-90’s diet directed research had
bolstered this involved form of dietary intervention with promising results. Randomized
controlled trials of MNT have reported decreases in HbA1c (A1C) of 1% in type 1 diabetics
and 1–2% in type 2 diabetics, depending on the duration of diabetes. After initiation of MNT,
improvements were apparent in 3–6 months.[10,37,38]
3.2. Lipid management
Both types of diabetes associated with a substantially increased risk of atherosclerotic vascular
disease, identification of treatments for the prevention of major occlusive vascular events is a
public-health priority.[39,40,41] The most recent meta-analyses have underscored the impor‐
tance of lipid management and have changed the medical communities general approach to
risk reduction in the diabetic community. There appears to be an approximately linear
relationship between the absolute reductions in LDL cholesterol achieved in these trials and
the proportional reductions in the incidence of major vascular events.[42,43] The implications
of this is far reaching. What used to be a categorical approach with a goal cholesterol level in
mind has broadened considerably. In all patients with diabetes over the age of 40 years
moderate intensity statin treatment should be considered, in addition to lifestyle therapy
(Table 3). If the patient falls under a ‘high-risk’ category—those with acute coronary syn‐
dromes or previous cardiovascular events, LDL cholesterol > 100mg/dL, high blood pressure,
currently smoking and/or overweight should have more aggressive therapy with high doses
of statins.[44,45] This strategy should be coupled with medical nutritional therapy.
3.2.1. Aspirin therapy
In general, patients with or without diabetes, who have known occlusive vascular disease,
stand to benefit from long-term antiplatelet therapy with aspirin, reducing the yearly risk of
serious vascular events. The benefits of antiplatelet therapy substantially exceed the risk of
major bleeding events and it is therefore widely accepted as means of secondary prevention.
For primary prevention, however, the balance is less clear with no single trial demonstrating
a clear benefit.[46,47] In order to reconcile the uncertainty regarding primary prevention the
American Diabetes Association performed a meta-analysis that added data from additional
trials performed specifically in patients with diabetes to the data from the subgroups of
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patients with diabetes from the six trials included in the ATT (Antiplatelet Trialists' Collabo‐
ration Collaborative) meta-analysis. They concluded that aspirin appears to produce a modest-
sized reduction in MI and stroke in patients with diabetes, but current evidence remains
inconclusive. This was partially rectified by recent 14 trial meta-analysis which found a
significant net benefit, but the authors still concluded inconclusiveness in regards to diabetic
patients.[48,49,50]
In 2010, a position statement of the ADA, the American Heart Association, and the American
College of Cardiology Foundation recommended physicians consider aspirin therapy (75–162
mg/day) as a primary prevention strategy in those with type 1 or type 2 diabetes at increased
cardiovascular risk (10-year risk >10%). This includes most men aged >50 years or women aged
>60 years who have at least one additional major risk factor (family history of CVD, hyper‐
tension, smoking, dyslipidemia, or albuminuria). However, aspirin was no longer recom‐
mended for those at low CVD risk (women under age 60 years and men under age 50 years
with no major CVD risk factors; 10-year CVD risk under 5%) as the low benefit is likely to be
outweighed by the risks of significant bleeding.[27]
3.3. Anti-diabetic medications and cardiovascular disease
Several classes of antidiabetic medications are currently available and effectively decreased
hyperglycemia; however, concern regarding increased CVD risk was raised with the publica‐
tion of the famous metanalysis by Nissen et al (2007) and showed rosiglitazone to be associated
Age Risk factors Recommended statin
dose*
Monitoring with lipid
panel
< 40 years None
CVD risk factor(s)**
Overt CVD***
None
Moderate or high
High
Annually or as needed to
monitor for adherence
40-75 years None
CVD risk factors
Overt CVD
Moderate
High
High
As needed to monitor
adherence
>75 years None
CVD risk factors
Overt CVD
Moderate
Moderate or high
High
As needed to monitor
adherence
* Moderate-Intensity Statin Therapy: Atorvastatin 10-20 mg, Rosuvastatin 5-10 mg, Simvastatin 20-40 mg, Pravastatin
40-80 mg, Lovastatin 40 mg. High-Intensity Statins Therapy: Atorvastatin 80 mg, Rosuvastatin 20-40 mg
**CVD risk factors include LDL cholesterol $100 mg/dL (2.6 mmol/L), high blood pressure,
smoking, and overweight and obesity.
***Overt CVD includes those with previous cardiovascular events or acute coronary syndromes.
Adapted from Diabetes Care Volume 38, Supplement 1, January 2015 [2]
Table 3. Recommendations for statin treatment in people with diabetes
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with a significant increase in the risk of myocardial infarction and with an increase in the risk
of death from cardiovascular causes that had borderline significance. This study eventually,
as well as other concerns, led to the withdrawal of the medication from the European Union
as well as severe restriction that amounted to effective withdrawal in the United States as well.
These findings also prompted the FDA to require cardiovascular safety data prior to approval
of new diabetes drugs in the USA. Currently, evidence available regarding cardiovascular
safety and even protective effects for metformin either neutral or uncertain effects of others
agents due to lack of long-term safety data.
4. Global control of cardiovascular risk in the diabetic population
The estimation and categorization of cardiovascular risk requires close attention to the risks
being explored (Table 4). While certain CVD risks are modifiable such as smoking, obesity,
hypertension and dyslipidemia, others are non-modifiable such as family history of premature
coronary artery disease. Despite evidence for improved CVD outcomes with control of CVD
risk factors, data from our group (McFarlane et al., 2002, 2005) conducted at multiple centers
in the USA, among various ethnic groups and practice settings, showed largely suboptimal
control of glycemia, blood pressure, and cholesterol and also demonstrated gender disparity
in the outcomes of diabetic care. For these reasons, a multifactorial targeted and evidence based
approach as detailed in this chapter needs to be employed for the appropriate and adequate
management of these diabetic patients at risk for cardiovascular disease.
Modifiable Risk Factors Non-Modifiable Risk Factors
Hypertension Age
Diabetes Sex
Dyslipidemia Race/Ethnicity
Tobacco Use Family history of premature CAD
Poor dietary habits ( high fat, high carbohydrate)
Sedentary lifestyle
Obesity ( particularly central distribution)
microalbuminuria
Increased inflammation
Stimulation of RAAS
CAD= Coronary artery disease
RAAS = Renin Angiotensin Aldosterone System
Table 4. Risk Factor Categorization
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